Skip to main content


Fig. 1 | BMC Cancer

Fig. 1

From: The effects of lymph node status on predicting outcome in ER+ /HER2- tamoxifen treated breast cancer patients using gene signatures

Fig. 1

Performance of Gene Signatures. Comparison of hazard ratios (HR) with 95 % confidence intervals from Oncotype DX, Prosigna, and Ellen. Signature performance on LN- patients (a) and LN+ patients (b) exclusively. Cumulative survival (Cum Survival) over 10 years of follow-up is demonstrated using Kaplan-Meier survival curves. Individual curves represent median cut-points of Oncotype DX (c and d), Prosigna (e and f), and Ellen (g and h) signatures that are shown for by LN- (c, e, and g) and LN+ (d, f, and h) patients respectively. The curves represent patients at high or low risk of metastasis

Back to article page